FIELD: medicine.
SUBSTANCE: group of inventions can be used for treating a malignant tumor in an individual in need thereof. That is ensured by administering an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof and RAF type 1 inhibitor or a pharmaceutically acceptable salt thereof. RAF type 1 inhibitor is selected from a group consisting of dabrafenib, TAK 632, vemurafenib, their pharmaceutically acceptable salts. Administration of said agents against malignant tumors provides a synergetic effect compared to introduction of any of these agents against tumors separately. Also disclosed are methods, pharmaceutical compositions and sets for treating a tumor.
EFFECT: group of inventions provides treatment of tumors in an individual due to synergistic action of said agents.
55 cl, 58 dwg, 18 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH BRAF ATYPICAL MUTATIONS | 2018 |
|
RU2812706C2 |
| METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING MALIGNANT TUMOUR | 2016 |
|
RU2718499C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| CELL | 2014 |
|
RU2732236C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| CELL | 2014 |
|
RU2717984C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
